Chengdu Easton Biopharmaceuticals Hits Day Low of CNY 48 Amid Price Pressure

Chengdu Easton Biopharmaceuticals Co., Ltd. experienced a significant decline today, with the stock dropping by 10.24% and reaching an intraday low of CNY 48.00. This performance stands in contrast to the China Shanghai Composite, which gained 0.96% on the same day. Over the past week, the stock has seen a decrease of 10.19%, and its monthly performance reflects a more substantial drop of 22.24%. Despite a notable annual return of 40.29%, the company has faced challenges, including a 4.7% decline in profits over the past year. The stock's operating cash flow reached a high of CNY 335.41 million, while raw material costs have decreased by 1.58% year-over-year. The company's debt-equity ratio stands at a low -48.64%, indicating a strong balance sheet. Chengdu Easton Biopharmaceuticals has a market capitalization of CNY 10,239 million and a price-to-earnings ratio of 44.00. With a dividend yield of 0.50% and a return on equity of 7.99%, the company continues to navigate a complex market landscape.